

THE TAMIL NADU Dr.M.G.R.MEDICAL UNIVERSITY, CHENNAI

RESULT OF THE Ph.D. STUDENTS - SCREENING COMMITTEE – JANUARY' 2018 SESSION

Sl. No.	NAME OF THE CANDIDATE	SPECIALITY	REMARKS OF THE SCREENING COMMITTEE	RESULT
1	Dr.Amit Kumar Dutta, D.M.	Medical	<p>1. Increase in sample size with respect to Crohn's Disease</p> <p>a) Exclusion (Antibiotics, Genobiotics and Steroids) especially in view of various time points.</p> <p>b) If flare up - may be interactive and clinically relevant and including sizeable population with flare up as limits of study may be recommended.</p> <p>2. Sample collection - Both quantitative and qualitative to be committed.</p> <p>3. RNA Extraction to be done as early (Further 24 hours of sample collection)</p> <p>4. Control should be not only age mentioned but should be region matched and hence study population from limited e.g. South as per the candidate's assurance .</p>	Accepted With Recommendations
2	Dr.A.Precilla Catherine, M.D.	Medical	<p>1. What is the clinical usefulness of the study result to the society / patients?</p> <p>2. Only sick patients are sent to CT Scan in Tertiary Government Hospital?</p> <p>a) How the sick patient information can be extrapolated to the general public.</p> <p>b) Using the same how do you calculate the incidence?</p>	Not Accepted

Sl. No.	NAME OF THE CANDIDATE	SPECIALITY	REMARKS OF THE SCREENING COMMITTEE	RESULT
			<p>3. What is the rationale for wide range of age group</p> <p>a) Specific to younger female for CT and ethical concern.</p> <p>4. Regarding measurements in CT Scan :</p> <p>a) Not demonstrated the automated software measurement of fat.</p> <p>b) Cannot promote single vendor.</p> <p>c) Manual measurement of visual / subcutaneous and total fat need to be demonstrated with images.</p> <p>d) Method of subtraction – by automated / manual method to be addressed.</p> <p>e) Why only L₄₋₅ level is selected ? How do you justify android and gynaecoid type of fat distribution ?</p> <p>5. In USG measurements :</p> <p>a) How to prove no compression during measurements ?</p> <p>b) How to eliminate intra observer measurement variation.</p> <p>c) Using linear parts can vertical diameter measurement be covered within the total zone in obese patient.</p> <p>6. What are the current cutoff values of Indian Standard taken for the study ?</p> <p>7. Provide the details of the various Indians proved the correlation of amount of visual fat to the various high risk parameters and followups.</p>	
3	Dr.P.Niveditha, M.D.	Medical	1. Diagnosis of GDM – OGCT is a screening test. More specific diagnostic test has to be done.	Not Accepted

Sl. No.	NAME OF THE CANDIDATE	SPECIALITY	REMARKS OF THE SCREENING COMMITTEE	RESULT
			<p>2. How is the patient who is diagnosed with GDM, going to be monitored from the time of diagnosis until delivery.</p> <p>If all patients, irrespective of the glycemic control status, are included in the study, it is likely to influence the outcome of the study.</p> <p>3. Baby needs to be followed up until 28 days.</p> <p>4. Patient who show elevated Triglycerides at the time of diagnosis of GDM are to be included in the study or not ?</p>	
4	Dr.P.Arunkumaran, M.D.	Medical		Accepted
5	Dr.Sumith K Mathew, M.D.	Medical		Accepted
6	Dr.M.S.Ahil, M.D.	Medical	<p>1. All the patients who are on carbamazepine should be included in the study. The sample size and methodology has to be revised accordingly. This proposal is approved with recommendation.</p>	Accepted With Recommendations
7	Dr.R.Padmavathi, M.D.	Medical	<p>I</p> <ol style="list-style-type: none"> 1. No research question. 2. Need preliminary data. 3. Data on number of patients being treated with targeted therapy. 4. Rework on sample size; inclusion and exclusion criteria. <p>II</p> <ol style="list-style-type: none"> 1. Formulate Research question. 2. Preliminary data on the spectrum of histomorphological features of lung carcinoma along with the staging. 3. Prognostication need not be included. 4. Sample Size need to be calculated. 	Not Accepted

Sl. No.	NAME OF THE CANDIDATE	SPECIALITY	REMARKS OF THE SCREENING COMMITTEE	RESULT
			<p>III</p> <ol style="list-style-type: none"> 1. Formulate a research question - What is described standard of care. 2. Provide data on the clinico-pathologic features of lung carcinoma seen over a specified time period, age, sex, relevant history, stage at presentation, spectrum of histological diagnosis, source of tissues. 3. Exclude prognosis because it may be difficult to get adequate data. 4. Chromosome analysis not mentioned in hand-out. Needs fresh tissue – stored samples may not be adequate. 5. ROS1 is required to be analysed. 	
8	Dr.K.Rajamaheswari, M.D.(S)	Siddha	<ol style="list-style-type: none"> 1. Dose mentioned in literature is to be followed. 2. Tropionin-T is to be tested and not all the Tropionins. 3. Suitable animal models like Ligation – Reperfusion injury may be used instead of isoproterenol - induced models. 4. As vitamin C has role in platelets, lemon juice should also be an arm in invitro. 	Approved With Modifications.
9	Mr.P.Yesudas Sudhakar M.Sc.	Basic Sciences	<ol style="list-style-type: none"> 1. Study lacks novelty with regard to the genes and antioxidant enzymes given in the proposal. 2. Sample size calculation is not done correctly. All the SNPs should be considered. 3. Assays for antioxidant enzymes lacks novelty and seems too peripheral. 4. Suggested to focus on one or two genes and undertake an in depth study. 	Not Accepted

Sl. No.	NAME OF THE CANDIDATE	SPECIALITY	REMARKS OF THE SCREENING COMMITTEE	RESULT
10	Mrs.K.Premavathi	Pharmacy		Accepted
11	Mr.N.Manikandan	Pharmacy	<ul style="list-style-type: none"> Presented as 'DBT' funded research. Clarification is required whether 'DBT' would allow the same study to be considered for Ph.D. title. 	Accepted With Recommendations
12	Mrs.D.Bharathi	Pharmacy	<ul style="list-style-type: none"> IEC approval has been obtained only for 3 molecules with 2 dose levels each. But, 18 molecules have been proposed for study. The candidate has to obtain IEC approval for the appropriate number of animals. 	Accepted With Recommendations
13	Mrs.P.K.Anamika	Pharmacy		Accepted
14	Mr.S.A.Mohamed Shiek Arabath	Pharmacy		Accepted
15	Mr.S.Senthilkumar	Pharmacy		Accepted
16	Mr.K.Abdulkhayum	Pharmacy		Accepted
17	Mrs.M.Sangeetha	Pharmacy	<ul style="list-style-type: none"> The candidate lacks insight of the study. Content of the proposed study and presentation are not 'on par' with the expected standards for Ph.D. title. 	Not Accepted
18	Mr.N.Jegan	Pharmacy	<ul style="list-style-type: none"> Number of animals approved by IEC for the study is insufficient. With the currently approved number of animals, the study is not feasible. 	Accepted With Recommendations
19	Mrs.K.N.Jiji	Pharmacy		Accepted
20	Mr.R.Prabhu	Pharmacy		Accepted

Sl. No.	NAME OF THE CANDIDATE	SPECIALITY	REMARKS OF THE SCREENING COMMITTEE	RESULT
21	Mr.Dara Anish Kumar	Pharmacy		Accepted
22	Mrs.B.Sugithra	Pharmacy		Withheld
23	Mrs.T.Uma Poorani	Pharmacy		Withheld
24	Mrs.C.Vijayalakshmi	Pharmacy		Withheld
25	Ms.P.Anandha Ruby	Nursing	<ul style="list-style-type: none"> To modify objectives, study designs and sample size. 	Accepted With Modifications
26	Ms.M.Malathi	Nursing	<ul style="list-style-type: none"> To drop soya and retain only turmeric. To retain study design. To re-write study proposal and submit. 	Accepted With Modifications
27	Ms.Helan Sujatha	Nursing	<ul style="list-style-type: none"> To include patient care giver in the study. FGD ID for patient care givers. IDI for patients. To revise study accordingly. 	Accepted With Modifications
28	Ms.Latha Venkatesh	Nursing	<ul style="list-style-type: none"> To revise study objectives and proposal as advised from exploration to KAP study in diabetics. 	Accepted With Modifications
29	Ms.P.C.Christol Joyce	Nursing	<ul style="list-style-type: none"> To revise the objectives from comparative to pre and post intervention study to the same group. Revise the study accordingly. 	Accepted With Modifications
30	Ms.P.N.Viji	Nursing		Not Accepted
31	Ms.Mary Sophia	Nursing	<ul style="list-style-type: none"> Intervention to both group at the beginning of the study. 	Accepted With Modifications
32	Ms.Glory Lilly Christy	Nursing	<ul style="list-style-type: none"> To change study area and revise the objective to KAP mortars on malnutrition (Pre-school) children. 	Accepted With Modifications
33	Ms.Ruth Johnson	Nursing	<ul style="list-style-type: none"> Revise and reduce the number of objectives as advised. Revise study accordingly. Sample size to be estimated accordingly. 	Accepted With Modifications

- ACCEPTED : Candidates are instructed to submit the joining report along with necessary fees through the Guide within 10 working days from the date of publication of result.
- ACCEPTED WITH RECOMMENDATION: Candidates are instructed to submit the Compliance Report through the Guide within 30 working days from the date of publication of results.
- NOT ACCEPTED : Candidates are instructed to submit proposals (Four copies) through the Guide within three months from the date of publication of this result.